Truth behind the discovery of mRNA vaccines with Robert Malone

Rob Malone’s fascination with retroviruses led to his exploration of RNA in the late 80s. • 1:33

Malone’s background in retroviral gene therapy influenced his interest in RNA and mRNA vaccines. • 3:14

Malone’s initial focus was on understanding how RNA of retroviruses assembles into live virus particles. • 4:39

RNA serves as a bridge between DNA and proteins in the process of gene expression. • 6:20

Retroviruses have a unique process involving RNA to DNA conversion, influencing Malone’s research direction. • 7:08

Initial research on retroviruses packaging RNA to produce viable retroviruses. • 7:47

Realization of using gene therapy technology to produce vaccines in the 1980s. • 9:18

Identification of immune response as a challenge in gene therapy and potential solution through vaccine development. • 11:03

Aha moment regarding the timeline of immune response in mice and gene therapy logic flaw. • 11:39

Recognition of the need to pivot from gene therapy to vaccine development for practical application. • 12:15

Research on mRNA in frog embryos led to unexpected success with chick embryos. • 13:30

Struggles with post-traumatic stress disorder and personal growth during PhD studies. • 15:24

Transition from Salk Institute to Vical led to significant breakthrough in mRNA research. • 17:31

Personal experiences and observations of toxic work environment at Salk Institute. • 18:48

Pressure cooker environment with multiple postdocs assigned to tasks. • 20:19

Initial excitement and ambition in a prestigious research environment. • 21:08

Struggle in receiving credit for pioneering work on mRNA vaccines. • 22:39

Ownership rights and restrictions leading to loss of research opportunities. • 23:01

Emotional impact likened to feeling of having creation taken away. • 24:15

Importance of academic recognition and citing intellectual contributions. • 25:08

Personal commitment to ensure proper credit for all contributions in the academic community. • 26:28

Dr. Malone expresses amazement at the efficiency of mRNA vaccines in gene therapy. • 27:38

Dr. Peter Cullis and his team played a crucial role in developing lipid formulations for mRNA vaccines. • 29:12

Despite the benefits, there are potential risks associated with the high efficiency of mRNA vaccines. • 30:11

Initial focus on drug repurposing over vaccine development during the early stages of the pandemic. • 31:20

Government decisions to invest in mRNA vaccine technology have been validated. • 32:49

Dr. Malone provided an independent assessment of data related to mRNA vaccine submissions in Japan. • 33:42

Documents uncovered in Canada raised safety concerns in vaccine recipients. • 34:51

Scientist requested to review and assess regulatory documents for transparency. • 35:50

Commitment to openness and transparency in sharing information about experimental products. • 37:21

Belief in the public’s ability to make informed decisions based on available information. • 38:16

Challenging scientific community to prevent group think and ensure safety in research. • 40:16

Independent assessment revealed unusual deficiencies in Pfizer’s regulatory submission. • 41:29

Discovery of unexpected biodistribution of mRNA vaccine in animal models • 41:58

Use of luciferase RNA in studies to detect protein expression • 43:11

Presence of injected material in distal sites and biological activity • 45:07

High concentration of lipids in ovaries compared to testis in rodents • 46:21

Expectation of injected material to spread through lymphatic system • 48:00

Formulations engineered to preferentially go through lymphatics to lymph nodes • 48:43

Systemic distribution of mRNA vaccines was not previously disclosed in literature • 49:26

Unexpected concentration in organs like ovaries raised concerns • 49:49

Selection bias in reporting vaccine-related events highlighted • 50:10

Subjective decisions play a role in determining vaccine-related events • 52:34

Observation of spike protein spreading systemically in the body discussed • 53:12

Research on distribution of RNA into cells and spike protein production mentioned • 54:44

Study involving nurses from Harvard and Brigham on vaccine effects cited • 55:29

Detection of free spike protein in nurses’ blood using sophisticated technology • 55:50

Significant levels of circulating spike protein found in nurses for a prolonged period • 56:33

Spike protein’s biological activity and potential to bind to ACE2 receptor in vascular endothelial cells • 58:10

Discussion on triggering autoimmune response post-vaccination and the importance of considering multiple hypotheses in science • 1:00:10

Adopting a method of multiple working hypotheses in scientific exploration • 1:01:18

Immune system responds to foreign protein complexes as different entities • 1:02:31

Delayed severe COVID-19 disease often linked to autoimmune response • 1:03:42

Thrombocytopenia and other symptoms consistent with autoimmune functions observed in COVID-19 patients • 1:05:11

Regulatory agencies require extensive safety data due to autoimmune disease risk • 1:06:44

Autoimmune diseases manifest over a longer time course, necessitating long-term safety follow-up • 1:08:07

Urgency to balance vaccine safety with the need to address the current COVID-19 crisis • 1:08:50

Discussion on the appropriateness of continuing mass vaccination, particularly in low-risk groups • 1:09:32

Concerns raised about safety signals and high levels of spike protein in the blood from mRNA vaccines • 1:10:24

Importance of full disclosure of risks to patients, especially adolescents who cannot provide full informed consent • 1:13:10

Identification of safety signal for cardiomyopathy in adolescent population receiving mRNA vaccines • 1:14:46

Lack of confidence in vaccine safety due to discrepancies in reported data and confirmation of safety signals • 1:16:06

Government history of tolerating risks in vaccine programs • 1:16:46

Subjective nature of risk-benefit ratio in vaccine decision-making • 1:18:13

Importance of informed consent for adolescents receiving experimental vaccines • 1:20:03

Caution against vaccinating adolescents with evolving safety data • 1:21:37

Historical ethical dilemmas in public health decision-making • 1:22:08

Need for rigorous safety data disclosure from other countries • 1:23:26

Importance of full disclosure of risks to patients • 1:24:09

Need for public comprehension of disclosed risks • 1:24:50

Belief in individual choice regarding experimental vaccines • 1:25:12

Acknowledgment of the timeliness and relevance of the discussion • 1:25:54

Expressing gratitude for the conversation and anticipation of future discussions • 1:26:17